X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALKEM LABORATORIES   ADCOCK INGRAM
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
ADCOCK INGRAM
Jun-14
ALKEM LABORATORIES/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,589381-   
Low Rs1,232275-   
Sales per share (Unadj.) Rs417.5113.4-  
Earnings per share (Unadj.) Rs56.3-28.6-  
Cash flow per share (Unadj.) Rs64.7-23.7-  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.989.0-  
Shares outstanding (eoy) m119.57168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.9 116.8%   
Avg P/E ratio x25.1-11.5 -218.2%  
P/CF ratio (eoy) x21.8-13.9 -157.3%  
Price / Book Value ratio x4.83.7 130.6%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,65355,398 304.4%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m9,1713,477 263.8%   
Avg. sales/employee Rs ThNM4,459.9-  
Avg. wages/employee Rs ThNM809.9-  
Avg. net profit/employee Rs ThNM-1,123.8-  
INCOME DATA
Net Sales Rs m49,91519,146 260.7%  
Other income Rs m1,645134 1,227.0%   
Total revenues Rs m51,56119,280 267.4%   
Gross profit Rs m8,482-3,318 -255.6%  
Depreciation Rs m1,006826 121.7%   
Interest Rs m671519 129.3%   
Profit before tax Rs m8,451-4,529 -186.6%   
Minority Interest Rs m-114-13 901.5%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606283 567.5%   
Profit after tax Rs m6,731-4,824 -139.5%  
Gross profit margin %17.0-17.3 -98.1%  
Effective tax rate %19.0-6.2 -304.1%   
Net profit margin %13.5-25.2 -53.5%  
BALANCE SHEET DATA
Current assets Rs m27,06214,023 193.0%   
Current liabilities Rs m15,3247,890 194.2%   
Net working cap to sales %23.532.0 73.4%  
Current ratio x1.81.8 99.4%  
Inventory Days Days67111 60.0%  
Debtors Days Days41124 33.3%  
Net fixed assets Rs m12,6108,174 154.3%   
Share capital Rs m23989 269.0%   
"Free" reserves Rs m34,4900-   
Net worth Rs m35,02715,028 233.1%   
Long term debt Rs m1,2125,281 22.9%   
Total assets Rs m54,38728,389 191.6%  
Interest coverage x13.6-7.7 -175.9%   
Debt to equity ratio x00.4 9.8%  
Sales to assets ratio x0.90.7 136.1%   
Return on assets %13.6-15.2 -89.7%  
Return on equity %19.2-32.1 -59.9%  
Return on capital %24.9-19.8 -125.5%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Net fx Rs m3,5520-   
CASH FLOW
From Operations Rs m7,2591,634 444.1%  
From Investments Rs m1,864-502 -371.5%  
From Financial Activity Rs m-9,2734,793 -193.5%  
Net Cashflow Rs m-1505,925 -2.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.26 Rs / ZAR

Compare ALKEM LABORATORIES With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare ALKEM LABORATORIES With: ORCHID PHARMA LTD  IPCA LABS  DIVIS LABORATORIES  LUPIN LTD  DR. REDDYS LAB  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 23, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS